Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 11/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 11/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.39 |
| ▸ | OPRL1 | P41146 | 11/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13543953 | 0.78 | OPRM1 (0.41) | CYP2D6OPRM1OPRD1OPRK1MEN1 | |
| SCHEMBL4100968 | 0.75 | CYP2D6 (0.47) | CYP2D6PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL26206626 | 0.70 | CYP2D6 (0.42) | CYP2D6PARP1OPRM1OPRD1OPRK1 | |
| SCHEMBL23064596 | 0.70 | NPSR1 (0.36) | OPRM1OPRD1OPRK1OPRL1SMN1; SMN2 | |
| SCHEMBL13330404 | 0.69 | OPRM1 (0.39) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL902468 | 0.69 | SLC6A4 (0.36) | CYP2D6OPRM1OPRD1MEN1CYP1A2 | |
| SCHEMBL9960510 | 0.69 | MEN1 (0.44) | OPRM1OPRD1OPRK1SMN1; SMN2MEN1 | |
| SCHEMBL8416690 | 0.67 | OPRM1 (0.43) | OPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL8221272 | 0.66 | TSHR (0.42) | OPRM1OPRD1OPRK1TSHR | |
| SCHEMBL28159048 | 0.66 | AKR1C1 (0.45) | CYP2D6OPRM1OPRD1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8039467-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-7652020-B2 | novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction | SCHERING CORPORATION (US) | 2010-01-26 | — | — | US | disclosed |
| US-7638513-B2 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | SCHERING CORPORATION | 2007-07-19 | — | — | US | disclosed |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | SCHERING CORPORATION | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167426-A1 | Compounds for the treatment of inflammatory disorders and microbial diseases | MMP12, ADAMTS1, ADAM33 | CYP2D6 2024/4885PARP1 1825/4885OPRM1 4080/4885 |
| US-20060178366-A1 | Compounds for the treatment of inflammatory disorders | MMP12, ADAMTS1, TNF | CYP2D6 2006/4885PARP1 1311/4885OPRM1 2806/4885 |
| US-20100145048-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, MMP12, MMP8 | CYP2D6 983/4885PARP1 2641/4885OPRM1 2369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.